Danaher Co. (NYSE:DHR) Shares Sold by Biltmore Family Office LLC

Biltmore Family Office LLC cut its position in shares of Danaher Co. (NYSE:DHR) by 4.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,727 shares of the conglomerate’s stock after selling 84 shares during the period. Biltmore Family Office LLC’s holdings in Danaher were worth $481,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. MQS Management LLC acquired a new stake in shares of Danaher in the first quarter worth $230,000. CreativeOne Wealth LLC purchased a new position in Danaher in the first quarter valued at about $250,000. Advisors Asset Management Inc. lifted its stake in shares of Danaher by 3.2% during the first quarter. Advisors Asset Management Inc. now owns 9,277 shares of the conglomerate’s stock worth $2,317,000 after purchasing an additional 290 shares in the last quarter. Bank of Nova Scotia Trust Co. grew its stake in shares of Danaher by 0.4% in the first quarter. Bank of Nova Scotia Trust Co. now owns 42,598 shares of the conglomerate’s stock valued at $10,638,000 after buying an additional 165 shares in the last quarter. Finally, Magnetar Financial LLC raised its holdings in shares of Danaher by 298.2% during the 1st quarter. Magnetar Financial LLC now owns 140,503 shares of the conglomerate’s stock valued at $35,086,000 after buying an additional 105,216 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $234.76 on Friday. The stock has a market capitalization of $169.56 billion, a P/E ratio of 44.80, a P/E/G ratio of 4.25 and a beta of 0.85. The firm’s 50-day moving average price is $258.92 and its two-hundred day moving average price is $259.96. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Raymond James lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Royal Bank of Canada dropped their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company initiated coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.